#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Sarcopenia was first described in 1988 as the age-related decline of skeletal muscle mass .
1-1	0-10	Sarcopenia	substance	new	coref	2-14
1-2	11-14	was	_	_	_	_
1-3	15-20	first	_	_	_	_
1-4	21-30	described	_	_	_	_
1-5	31-33	in	_	_	_	_
1-6	34-38	1988	time	new	_	_
1-7	39-41	as	_	_	_	_
1-8	42-45	the	_	_	_	_
1-9	46-57	age-related	_	_	_	_
1-10	58-65	decline	_	_	_	_
1-11	66-68	of	_	_	_	_
1-12	69-77	skeletal	quantity[4]	new[4]	coref	2-24[13_4]
1-13	78-84	muscle	object|quantity[4]	new|new[4]	coref	2-19
1-14	85-89	mass	quantity[4]	new[4]	_	_
1-15	90-91	.	_	_	_	_

#Text=In the last decade , several international groups have developed operational definitions of sarcopenia which incorporate assessments of muscle function in addition to muscle mass in sarcopenia case-finding guidelines .
2-1	92-94	In	_	_	_	_
2-2	95-98	the	time[5]	new[5]	_	_
2-3	99-103	last	time[5]	new[5]	_	_
2-4	104-110	decade	time[5]	new[5]	_	_
2-5	111-112	,	_	_	_	_
2-6	113-120	several	person[6]	new[6]	_	_
2-7	121-134	international	person[6]	new[6]	_	_
2-8	135-141	groups	person[6]	new[6]	_	_
2-9	142-146	have	_	_	_	_
2-10	147-156	developed	_	_	_	_
2-11	157-168	operational	abstract[7]	new[7]	_	_
2-12	169-180	definitions	abstract[7]	new[7]	_	_
2-13	181-183	of	abstract[7]	new[7]	_	_
2-14	184-194	sarcopenia	abstract[7]|abstract	new[7]|giv	coref	2-27
2-15	195-200	which	_	_	_	_
2-16	201-212	incorporate	_	_	_	_
2-17	213-224	assessments	abstract[9]	new[9]	coref	8-12[94_9]
2-18	225-227	of	abstract[9]	new[9]	_	_
2-19	228-234	muscle	abstract[9]|object|abstract[11]	new[9]|giv|new[11]	coref|coref|coref|coref	2-24|7-49[85_11]|2-24|7-49[85_11]
2-20	235-243	function	abstract[9]|abstract[11]	new[9]|new[11]	_	_
2-21	244-246	in	abstract[9]|abstract[11]	new[9]|new[11]	_	_
2-22	247-255	addition	abstract[9]|abstract[11]	new[9]|new[11]	_	_
2-23	256-258	to	abstract[9]|abstract[11]	new[9]|new[11]	_	_
2-24	259-265	muscle	abstract[9]|abstract[11]|object|quantity[13]	new[9]|new[11]|giv|giv[13]	coref|coref|coref|coref	6-10|8-13[0_13]|6-10|8-13[0_13]
2-25	266-270	mass	abstract[9]|abstract[11]|quantity[13]	new[9]|new[11]|giv[13]	_	_
2-26	271-273	in	abstract[9]|abstract[11]|quantity[13]	new[9]|new[11]|giv[13]	_	_
2-27	274-284	sarcopenia	abstract[9]|abstract[11]|quantity[13]|abstract|abstract[16]	new[9]|new[11]|giv[13]|giv|new[16]	coref|coref	3-31|3-31
2-28	285-297	case-finding	abstract[9]|abstract[11]|quantity[13]|abstract|abstract[16]	new[9]|new[11]|giv[13]|new|new[16]	coref	6-18[59_0]
2-29	298-308	guidelines	abstract[9]|abstract[11]|quantity[13]|abstract[16]	new[9]|new[11]|giv[13]|new[16]	_	_
2-30	309-310	.	_	_	_	_

#Text=Nonetheless , recent changes to these recommendations demonstrate that there is significant work to be done in order to achieve an international consensus on the methods to diagnose and treat sarcopenia in clinical settings .
3-1	311-322	Nonetheless	_	_	_	_
3-2	323-324	,	_	_	_	_
3-3	325-331	recent	abstract[17]	new[17]	_	_
3-4	332-339	changes	abstract[17]	new[17]	_	_
3-5	340-342	to	abstract[17]	new[17]	_	_
3-6	343-348	these	abstract[17]|abstract[18]	new[17]|new[18]	_	_
3-7	349-364	recommendations	abstract[17]|abstract[18]	new[17]|new[18]	_	_
3-8	365-376	demonstrate	_	_	_	_
3-9	377-381	that	_	_	_	_
3-10	382-387	there	_	_	_	_
3-11	388-390	is	_	_	_	_
3-12	391-402	significant	abstract[19]	new[19]	_	_
3-13	403-407	work	abstract[19]	new[19]	_	_
3-14	408-410	to	_	_	_	_
3-15	411-413	be	_	_	_	_
3-16	414-418	done	_	_	_	_
3-17	419-421	in	_	_	_	_
3-18	422-427	order	_	_	_	_
3-19	428-430	to	_	_	_	_
3-20	431-438	achieve	_	_	_	_
3-21	439-441	an	abstract[20]	new[20]	_	_
3-22	442-455	international	abstract[20]	new[20]	_	_
3-23	456-465	consensus	abstract[20]	new[20]	_	_
3-24	466-468	on	abstract[20]	new[20]	_	_
3-25	469-472	the	abstract[20]|abstract[21]	new[20]|new[21]	_	_
3-26	473-480	methods	abstract[20]|abstract[21]	new[20]|new[21]	_	_
3-27	481-483	to	_	_	_	_
3-28	484-492	diagnose	_	_	_	_
3-29	493-496	and	_	_	_	_
3-30	497-502	treat	_	_	_	_
3-31	503-513	sarcopenia	abstract	giv	coref	4-4
3-32	514-516	in	_	_	_	_
3-33	517-525	clinical	abstract[23]	new[23]	coref	11-10[127_23]
3-34	526-534	settings	abstract[23]	new[23]	_	_
3-35	535-536	.	_	_	_	_

#Text=Indeed , while sarcopenia is now recognised with its own International Classification of Diseases , 10th Revision , Clinical Modification ( ICD-10-CM ) code ( M62.84 ) , few health care professionals know how to diagnose it , include it as part of their clinical practice , or even recognise it as a disease , .
4-1	537-543	Indeed	_	_	_	_
4-2	544-545	,	_	_	_	_
4-3	546-551	while	_	_	_	_
4-4	552-562	sarcopenia	abstract	giv	ana	4-9
4-5	563-565	is	_	_	_	_
4-6	566-569	now	_	_	_	_
4-7	570-580	recognised	_	_	_	_
4-8	581-585	with	_	_	_	_
4-9	586-589	its	abstract|abstract[26]	giv|new[26]	ana|ana	4-37|4-37
4-10	590-593	own	abstract[26]	new[26]	_	_
4-11	594-607	International	abstract[26]	new[26]	_	_
4-12	608-622	Classification	abstract[26]	new[26]	_	_
4-13	623-625	of	abstract[26]	new[26]	_	_
4-14	626-634	Diseases	abstract[26]|abstract	new[26]|new	_	_
4-15	635-636	,	_	_	_	_
4-16	637-641	10th	abstract[28]	new[28]	_	_
4-17	642-650	Revision	abstract[28]	new[28]	_	_
4-18	651-652	,	_	_	_	_
4-19	653-661	Clinical	substance|abstract[30]|abstract[32]	new|new[30]|new[32]	appos|appos|appos|appos|appos|appos	4-22[0_30]|4-26[0_32]|4-22[0_30]|4-26[0_32]|4-22[0_30]|4-26[0_32]
4-20	662-674	Modification	abstract[30]|abstract[32]	new[30]|new[32]	_	_
4-21	675-676	(	abstract[32]	new[32]	_	_
4-22	677-686	ICD-10-CM	abstract|abstract[32]	giv|new[32]	_	_
4-23	687-688	)	abstract[32]	new[32]	_	_
4-24	689-693	code	abstract[32]	new[32]	_	_
4-25	694-695	(	_	_	_	_
4-26	696-702	M62.84	abstract	giv	_	_
4-27	703-704	)	_	_	_	_
4-28	705-706	,	_	_	_	_
4-29	707-710	few	person[36]	new[36]	ana	4-44[0_36]
4-30	711-717	health	abstract|person[36]	new|new[36]	_	_
4-31	718-722	care	abstract|person[36]	new|new[36]	_	_
4-32	723-736	professionals	person[36]	new[36]	_	_
4-33	737-741	know	_	_	_	_
4-34	742-745	how	_	_	_	_
4-35	746-748	to	_	_	_	_
4-36	749-757	diagnose	_	_	_	_
4-37	758-760	it	abstract	giv	ana	4-40
4-38	761-762	,	_	_	_	_
4-39	763-770	include	_	_	_	_
4-40	771-773	it	abstract	giv	ana	4-51
4-41	774-776	as	_	_	_	_
4-42	777-781	part	_	_	_	_
4-43	782-784	of	_	_	_	_
4-44	785-790	their	person|abstract[40]	giv|new[40]	_	_
4-45	791-799	clinical	abstract[40]	new[40]	_	_
4-46	800-808	practice	abstract[40]	new[40]	_	_
4-47	809-810	,	_	_	_	_
4-48	811-813	or	_	_	_	_
4-49	814-818	even	_	_	_	_
4-50	819-828	recognise	_	_	_	_
4-51	829-831	it	abstract	giv	coref	5-25
4-52	832-834	as	_	_	_	_
4-53	835-836	a	_	_	_	_
4-54	837-844	disease	_	_	_	_
4-55	845-846	,	_	_	_	_
4-56	847-848	.	_	_	_	_

#Text=This Special Issue of the Journal of Clinical Medicine was established with a view to increase clinician awareness of the important clinical consequences of sarcopenia and improve understanding of diagnosis and treatment strategies .
5-1	849-853	This	abstract[42]	new[42]	coref	7-21[74_42]
5-2	854-861	Special	abstract[42]	new[42]	_	_
5-3	862-867	Issue	abstract[42]	new[42]	_	_
5-4	868-870	of	abstract[42]	new[42]	_	_
5-5	871-874	the	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-6	875-882	Journal	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-7	883-885	of	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-8	886-894	Clinical	abstract[42]|abstract[43]	new[42]|new[43]	_	_
5-9	895-903	Medicine	abstract[42]|abstract[43]|abstract	new[42]|new[43]|new	_	_
5-10	904-907	was	_	_	_	_
5-11	908-919	established	_	_	_	_
5-12	920-924	with	_	_	_	_
5-13	925-926	a	abstract[45]	new[45]	_	_
5-14	927-931	view	abstract[45]	new[45]	_	_
5-15	932-934	to	_	_	_	_
5-16	935-943	increase	_	_	_	_
5-17	944-953	clinician	person|abstract[47]	new|new[47]	_	_
5-18	954-963	awareness	abstract[47]	new[47]	_	_
5-19	964-966	of	abstract[47]	new[47]	_	_
5-20	967-970	the	abstract[47]|abstract[48]	new[47]|new[48]	_	_
5-21	971-980	important	abstract[47]|abstract[48]	new[47]|new[48]	_	_
5-22	981-989	clinical	abstract[47]|abstract[48]	new[47]|new[48]	_	_
5-23	990-1002	consequences	abstract[47]|abstract[48]	new[47]|new[48]	_	_
5-24	1003-1005	of	abstract[47]|abstract[48]	new[47]|new[48]	_	_
5-25	1006-1016	sarcopenia	abstract[47]|abstract[48]|abstract	new[47]|new[48]|giv	coref	6-20
5-26	1017-1020	and	_	_	_	_
5-27	1021-1028	improve	_	_	_	_
5-28	1029-1042	understanding	abstract[50]	new[50]	_	_
5-29	1043-1045	of	abstract[50]	new[50]	_	_
5-30	1046-1055	diagnosis	abstract[50]|abstract	new[50]|new	_	_
5-31	1056-1059	and	abstract[50]	new[50]	_	_
5-32	1060-1069	treatment	abstract[50]|event|abstract[53]	new[50]|new|new[53]	_	_
5-33	1070-1080	strategies	abstract[50]|abstract[53]	new[50]|new[53]	_	_
5-34	1081-1082	.	_	_	_	_

#Text=Computed tomography ( CT ) provides precise estimates of muscle quality and so may be useful for case-finding in sarcopenia , but barriers to this method include high costs , lack of availability and ionising radiation doses .
6-1	1083-1091	Computed	object[54]	new[54]	appos	6-4[0_54]
6-2	1092-1102	tomography	object[54]	new[54]	_	_
6-3	1103-1104	(	_	_	_	_
6-4	1105-1107	CT	object	giv	coref	7-42
6-5	1108-1109	)	_	_	_	_
6-6	1110-1118	provides	_	_	_	_
6-7	1119-1126	precise	abstract[56]	new[56]	coref	7-35[81_56]
6-8	1127-1136	estimates	abstract[56]	new[56]	_	_
6-9	1137-1139	of	abstract[56]	new[56]	_	_
6-10	1140-1146	muscle	abstract[56]|object|abstract[58]	new[56]|giv|new[58]	coref|coref|coref|coref	7-13|7-13[71_58]|7-13|7-13[71_58]
6-11	1147-1154	quality	abstract[56]|abstract[58]	new[56]|new[58]	_	_
6-12	1155-1158	and	_	_	_	_
6-13	1159-1161	so	_	_	_	_
6-14	1162-1165	may	_	_	_	_
6-15	1166-1168	be	_	_	_	_
6-16	1169-1175	useful	_	_	_	_
6-17	1176-1179	for	_	_	_	_
6-18	1180-1192	case-finding	abstract[59]	giv[59]	_	_
6-19	1193-1195	in	abstract[59]	giv[59]	_	_
6-20	1196-1206	sarcopenia	abstract[59]|abstract	giv[59]|giv	coref	8-30
6-21	1207-1208	,	_	_	_	_
6-22	1209-1212	but	_	_	_	_
6-23	1213-1221	barriers	object[61]	new[61]	_	_
6-24	1222-1224	to	object[61]	new[61]	_	_
6-25	1225-1229	this	object[61]|abstract[62]	new[61]|new[62]	coref	7-3[69_62]
6-26	1230-1236	method	object[61]|abstract[62]	new[61]|new[62]	_	_
6-27	1237-1244	include	_	_	_	_
6-28	1245-1249	high	quantity[63]	new[63]	_	_
6-29	1250-1255	costs	quantity[63]	new[63]	_	_
6-30	1256-1257	,	_	_	_	_
6-31	1258-1262	lack	abstract[64]	new[64]	_	_
6-32	1263-1265	of	abstract[64]	new[64]	_	_
6-33	1266-1278	availability	abstract[64]|abstract	new[64]|new	_	_
6-34	1279-1282	and	abstract[64]	new[64]	_	_
6-35	1283-1291	ionising	abstract[64]|abstract[67]	new[64]|new[67]	_	_
6-36	1292-1301	radiation	abstract[64]|abstract|abstract[67]	new[64]|new|new[67]	_	_
6-37	1302-1307	doses	abstract[64]|abstract[67]	new[64]|new[67]	_	_
6-38	1308-1309	.	_	_	_	_

#Text=Ultrasound represents a potentially cost-effective , accessible and safe method of measuring muscle quality and Harris-Love and colleagues demonstrate in this special issue that rectus femoris echogenicity assessed by ultrasound is significantly correlated with intra- and inter-muscular adipose tissue estimates from CT , and has similar associations with muscle function and cardiometabolic outcomes .
7-1	1310-1320	Ultrasound	object	new	coref	7-30
7-2	1321-1331	represents	_	_	_	_
7-3	1332-1333	a	abstract[69]	giv[69]	_	_
7-4	1334-1345	potentially	abstract[69]	giv[69]	_	_
7-5	1346-1360	cost-effective	abstract[69]	giv[69]	_	_
7-6	1361-1362	,	abstract[69]	giv[69]	_	_
7-7	1363-1373	accessible	abstract[69]	giv[69]	_	_
7-8	1374-1377	and	abstract[69]	giv[69]	_	_
7-9	1378-1382	safe	abstract[69]	giv[69]	_	_
7-10	1383-1389	method	abstract[69]	giv[69]	_	_
7-11	1390-1392	of	_	_	_	_
7-12	1393-1402	measuring	_	_	_	_
7-13	1403-1409	muscle	object|abstract[71]	giv|giv[71]	coref|coref|coref|coref	7-49|12-31[149_71]|7-49|12-31[149_71]
7-14	1410-1417	quality	abstract[71]	giv[71]	_	_
7-15	1418-1421	and	_	_	_	_
7-16	1422-1433	Harris-Love	person	new	_	_
7-17	1434-1437	and	_	_	_	_
7-18	1438-1448	colleagues	person	new	coref	12-3
7-19	1449-1460	demonstrate	_	_	_	_
7-20	1461-1463	in	_	_	_	_
7-21	1464-1468	this	abstract[74]	giv[74]	coref	10-2[111_74]
7-22	1469-1476	special	abstract[74]	giv[74]	_	_
7-23	1477-1482	issue	abstract[74]	giv[74]	_	_
7-24	1483-1487	that	_	_	_	_
7-25	1488-1494	rectus	abstract|abstract[77]	new|new[77]	_	_
7-26	1495-1502	femoris	substance|abstract[77]	new|new[77]	_	_
7-27	1503-1515	echogenicity	abstract[77]	new[77]	_	_
7-28	1516-1524	assessed	_	_	_	_
7-29	1525-1527	by	_	_	_	_
7-30	1528-1538	ultrasound	abstract	giv	_	_
7-31	1539-1541	is	_	_	_	_
7-32	1542-1555	significantly	_	_	_	_
7-33	1556-1566	correlated	_	_	_	_
7-34	1567-1571	with	_	_	_	_
7-35	1572-1578	intra-	abstract[81]	giv[81]	_	_
7-36	1579-1582	and	abstract[81]	giv[81]	_	_
7-37	1583-1597	inter-muscular	abstract[81]	giv[81]	_	_
7-38	1598-1605	adipose	abstract|abstract[81]	new|giv[81]	_	_
7-39	1606-1612	tissue	object|abstract[81]	new|giv[81]	_	_
7-40	1613-1622	estimates	abstract[81]	giv[81]	_	_
7-41	1623-1627	from	abstract[81]	giv[81]	_	_
7-42	1628-1630	CT	abstract[81]|object	giv[81]|giv	coref	17-35
7-43	1631-1632	,	_	_	_	_
7-44	1633-1636	and	_	_	_	_
7-45	1637-1640	has	_	_	_	_
7-46	1641-1648	similar	abstract[83]	new[83]	coref	12-5[139_83]
7-47	1649-1661	associations	abstract[83]	new[83]	_	_
7-48	1662-1666	with	abstract[83]	new[83]	_	_
7-49	1667-1673	muscle	abstract[83]|object|abstract[85]	new[83]|giv|giv[85]	coref|coref|coref|coref	8-12|11-2[0_85]|8-12|11-2[0_85]
7-50	1674-1682	function	abstract[83]|abstract[85]	new[83]|giv[85]	_	_
7-51	1683-1686	and	abstract[83]	new[83]	_	_
7-52	1687-1702	cardiometabolic	abstract[83]|place|abstract[87]	new[83]|new|new[87]	_	_
7-53	1703-1711	outcomes	abstract[83]|abstract[87]	new[83]|new[87]	_	_
7-54	1712-1713	.	_	_	_	_

#Text=For clinicians without requisite expertise or access to equipment to perform muscle mass assessments , it is possible that questionnaires can be useful in identifying patients at risk of sarcopenia .
8-1	1714-1717	For	_	_	_	_
8-2	1718-1728	clinicians	person[88]	new[88]	_	_
8-3	1729-1736	without	person[88]	new[88]	_	_
8-4	1737-1746	requisite	person[88]|abstract[89]	new[88]|new[89]	_	_
8-5	1747-1756	expertise	person[88]|abstract[89]	new[88]|new[89]	_	_
8-6	1757-1759	or	person[88]	new[88]	_	_
8-7	1760-1766	access	person[88]|abstract[90]	new[88]|new[90]	_	_
8-8	1767-1769	to	person[88]|abstract[90]	new[88]|new[90]	_	_
8-9	1770-1779	equipment	person[88]|abstract[90]|object	new[88]|new[90]|new	_	_
8-10	1780-1782	to	_	_	_	_
8-11	1783-1790	perform	_	_	_	_
8-12	1791-1797	muscle	object|abstract[94]	giv|giv[94]	coref|coref|coref|coref	11-1[126_94]|11-31|11-1[126_94]|11-31
8-13	1798-1802	mass	quantity|abstract[94]	giv|giv[94]	coref	11-29[133_0]
8-14	1803-1814	assessments	abstract[94]	giv[94]	_	_
8-15	1815-1816	,	_	_	_	_
8-16	1817-1819	it	abstract	new	cata	8-16[0_97]
8-17	1820-1822	is	_	_	_	_
8-18	1823-1831	possible	_	_	_	_
8-19	1832-1836	that	abstract[97]	new[97]	_	_
8-20	1837-1851	questionnaires	abstract|abstract[97]	new|new[97]	_	_
8-21	1852-1855	can	abstract[97]	new[97]	_	_
8-22	1856-1858	be	abstract[97]	new[97]	_	_
8-23	1859-1865	useful	abstract[97]	new[97]	_	_
8-24	1866-1868	in	_	_	_	_
8-25	1869-1880	identifying	_	_	_	_
8-26	1881-1889	patients	person	new	coref	9-24[109_0]
8-27	1890-1892	at	_	_	_	_
8-28	1893-1897	risk	abstract[99]	new[99]	coref	10-31[119_99]
8-29	1898-1900	of	abstract[99]	new[99]	_	_
8-30	1901-1911	sarcopenia	abstract[99]|abstract	new[99]|giv	coref	9-4
8-31	1912-1913	.	_	_	_	_

#Text=The SarQoL® ( Sarcopenia and Quality of Life ) , is a validated quality of life ( QoL ) questionnaire which can discriminate sarcopenic and non-sarcopenic patients and has already been translated into several languages .
9-1	1914-1917	The	abstract[101]	new[101]	appos	9-4[103_101]
9-2	1918-1925	SarQoL®	abstract[101]	new[101]	_	_
9-3	1926-1927	(	_	_	_	_
9-4	1928-1938	Sarcopenia	abstract|abstract[103]	giv|giv[103]	coref|coref|coref|coref	9-12[105_103]|10-33|9-12[105_103]|10-33
9-5	1939-1942	and	abstract[103]	giv[103]	_	_
9-6	1943-1950	Quality	abstract[103]	giv[103]	_	_
9-7	1951-1953	of	abstract[103]	giv[103]	_	_
9-8	1954-1958	Life	abstract[103]|person	giv[103]|new	_	_
9-9	1959-1960	)	_	_	_	_
9-10	1961-1962	,	_	_	_	_
9-11	1963-1965	is	_	_	_	_
9-12	1966-1967	a	abstract[105]	giv[105]	coref	10-15[115_105]
9-13	1968-1977	validated	abstract[105]	giv[105]	_	_
9-14	1978-1985	quality	abstract[105]	giv[105]	_	_
9-15	1986-1988	of	abstract[105]	giv[105]	_	_
9-16	1989-1993	life	abstract[105]|abstract	giv[105]|new	appos	9-18
9-17	1994-1995	(	abstract[105]	giv[105]	_	_
9-18	1996-1999	QoL	abstract[105]|abstract	giv[105]|giv	coref	10-41
9-19	2000-2001	)	abstract[105]	giv[105]	_	_
9-20	2002-2015	questionnaire	abstract[105]|abstract	giv[105]|new	_	_
9-21	2016-2021	which	_	_	_	_
9-22	2022-2025	can	_	_	_	_
9-23	2026-2038	discriminate	_	_	_	_
9-24	2039-2049	sarcopenic	person[109]	giv[109]	coref	18-6[199_109]
9-25	2050-2053	and	person[109]	giv[109]	_	_
9-26	2054-2068	non-sarcopenic	person[109]	giv[109]	_	_
9-27	2069-2077	patients	person[109]	giv[109]	_	_
9-28	2078-2081	and	_	_	_	_
9-29	2082-2085	has	_	_	_	_
9-30	2086-2093	already	_	_	_	_
9-31	2094-2098	been	_	_	_	_
9-32	2099-2109	translated	_	_	_	_
9-33	2110-2114	into	_	_	_	_
9-34	2115-2122	several	abstract[110]	new[110]	_	_
9-35	2123-2132	languages	abstract[110]	new[110]	_	_
9-36	2133-2134	.	_	_	_	_

#Text=In this issue , a study on the validation of a Polish version of the SarQoL® is described , highlighting the potential utility of this instrument for identifying individuals at risk of sarcopenia , as well as its impact on QoL , across a number of countries worldwide .
10-1	2135-2137	In	_	_	_	_
10-2	2138-2142	this	abstract[111]	giv[111]	_	_
10-3	2143-2148	issue	abstract[111]	giv[111]	_	_
10-4	2149-2150	,	_	_	_	_
10-5	2151-2152	a	abstract[112]	new[112]	coref	16-11[177_112]
10-6	2153-2158	study	abstract[112]	new[112]	_	_
10-7	2159-2161	on	abstract[112]	new[112]	_	_
10-8	2162-2165	the	abstract[112]|abstract[113]	new[112]|new[113]	_	_
10-9	2166-2176	validation	abstract[112]|abstract[113]	new[112]|new[113]	_	_
10-10	2177-2179	of	abstract[112]|abstract[113]	new[112]|new[113]	_	_
10-11	2180-2181	a	abstract[112]|abstract[113]|abstract[114]	new[112]|new[113]|new[114]	_	_
10-12	2182-2188	Polish	abstract[112]|abstract[113]|abstract[114]	new[112]|new[113]|new[114]	_	_
10-13	2189-2196	version	abstract[112]|abstract[113]|abstract[114]	new[112]|new[113]|new[114]	_	_
10-14	2197-2199	of	abstract[112]|abstract[113]|abstract[114]	new[112]|new[113]|new[114]	_	_
10-15	2200-2203	the	abstract[112]|abstract[113]|abstract[114]|abstract[115]	new[112]|new[113]|new[114]|giv[115]	_	_
10-16	2204-2211	SarQoL®	abstract[112]|abstract[113]|abstract[114]|abstract[115]	new[112]|new[113]|new[114]|giv[115]	_	_
10-17	2212-2214	is	_	_	_	_
10-18	2215-2224	described	_	_	_	_
10-19	2225-2226	,	_	_	_	_
10-20	2227-2239	highlighting	_	_	_	_
10-21	2240-2243	the	abstract[116]	new[116]	_	_
10-22	2244-2253	potential	abstract[116]	new[116]	_	_
10-23	2254-2261	utility	abstract[116]	new[116]	_	_
10-24	2262-2264	of	abstract[116]	new[116]	_	_
10-25	2265-2269	this	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-26	2270-2280	instrument	abstract[116]|abstract[117]	new[116]|new[117]	_	_
10-27	2281-2284	for	_	_	_	_
10-28	2285-2296	identifying	_	_	_	_
10-29	2297-2308	individuals	person[118]	new[118]	coref	12-21[146_118]
10-30	2309-2311	at	person[118]	new[118]	_	_
10-31	2312-2316	risk	person[118]|abstract[119]	new[118]|giv[119]	coref	13-14[155_119]
10-32	2317-2319	of	person[118]|abstract[119]	new[118]|giv[119]	_	_
10-33	2320-2330	sarcopenia	person[118]|abstract[119]|abstract	new[118]|giv[119]|giv	ana	10-38
10-34	2331-2332	,	_	_	_	_
10-35	2333-2335	as	_	_	_	_
10-36	2336-2340	well	_	_	_	_
10-37	2341-2343	as	_	_	_	_
10-38	2344-2347	its	abstract|abstract[122]	giv|new[122]	coref|coref	11-19|11-19
10-39	2348-2354	impact	abstract[122]	new[122]	_	_
10-40	2355-2357	on	abstract[122]	new[122]	_	_
10-41	2358-2361	QoL	abstract[122]|abstract	new[122]|giv	_	_
10-42	2362-2363	,	abstract[122]	new[122]	_	_
10-43	2364-2370	across	abstract[122]	new[122]	_	_
10-44	2371-2372	a	abstract[122]|organization[124]	new[122]|new[124]	_	_
10-45	2373-2379	number	abstract[122]|organization[124]	new[122]|new[124]	_	_
10-46	2380-2382	of	abstract[122]|organization[124]	new[122]|new[124]	_	_
10-47	2383-2392	countries	abstract[122]|organization[124]	new[122]|new[124]	_	_
10-48	2393-2402	worldwide	abstract[122]	new[122]	_	_
10-49	2403-2404	.	_	_	_	_

#Text=Physical function assessments are also simple to perform in clinical settings and may be most appropriate to identify sarcopenia cases in obese older adults who , owing to their larger muscle mass , may generally exceed cut-off points for low muscle mass .
11-1	2405-2413	Physical	abstract[126]	giv[126]	_	_
11-2	2414-2422	function	abstract|abstract[126]	giv|giv[126]	coref	12-11[143_0]
11-3	2423-2434	assessments	abstract[126]	giv[126]	_	_
11-4	2435-2438	are	_	_	_	_
11-5	2439-2443	also	_	_	_	_
11-6	2444-2450	simple	_	_	_	_
11-7	2451-2453	to	_	_	_	_
11-8	2454-2461	perform	_	_	_	_
11-9	2462-2464	in	_	_	_	_
11-10	2465-2473	clinical	abstract[127]	giv[127]	_	_
11-11	2474-2482	settings	abstract[127]	giv[127]	_	_
11-12	2483-2486	and	_	_	_	_
11-13	2487-2490	may	_	_	_	_
11-14	2491-2493	be	_	_	_	_
11-15	2494-2498	most	_	_	_	_
11-16	2499-2510	appropriate	_	_	_	_
11-17	2511-2513	to	_	_	_	_
11-18	2514-2522	identify	_	_	_	_
11-19	2523-2533	sarcopenia	abstract|abstract[129]	giv|new[129]	coref|coref	13-1|13-1
11-20	2534-2539	cases	abstract[129]	new[129]	_	_
11-21	2540-2542	in	abstract[129]	new[129]	_	_
11-22	2543-2548	obese	abstract[129]|person[130]	new[129]|new[130]	ana	11-29[0_130]
11-23	2549-2554	older	abstract[129]|person[130]	new[129]|new[130]	_	_
11-24	2555-2561	adults	abstract[129]|person[130]	new[129]|new[130]	_	_
11-25	2562-2565	who	_	_	_	_
11-26	2566-2567	,	_	_	_	_
11-27	2568-2573	owing	_	_	_	_
11-28	2574-2576	to	_	_	_	_
11-29	2577-2582	their	person|quantity[133]	giv|giv[133]	coref|coref|coref|coref	11-40[136_133]|16-15[179_0]|11-40[136_133]|16-15[179_0]
11-30	2583-2589	larger	quantity[133]	giv[133]	_	_
11-31	2590-2596	muscle	object|quantity[133]	giv|giv[133]	coref	11-41
11-32	2597-2601	mass	quantity[133]	giv[133]	_	_
11-33	2602-2603	,	_	_	_	_
11-34	2604-2607	may	_	_	_	_
11-35	2608-2617	generally	_	_	_	_
11-36	2618-2624	exceed	_	_	_	_
11-37	2625-2632	cut-off	abstract[134]	new[134]	_	_
11-38	2633-2639	points	abstract[134]	new[134]	_	_
11-39	2640-2643	for	_	_	_	_
11-40	2644-2647	low	quantity[136]	giv[136]	coref	17-30[193_136]
11-41	2648-2654	muscle	object|quantity[136]	giv|giv[136]	coref	12-12
11-42	2655-2659	mass	quantity[136]	giv[136]	_	_
11-43	2660-2661	.	_	_	_	_

#Text=Mesinovic and colleagues demonstrate associations between the metabolic syndrome and poorer muscle function despite the generally larger muscle size in overweight and obese older individuals , indicating accelerated loss of muscle quality is common in this population .
12-1	2662-2671	Mesinovic	person	new	_	_
12-2	2672-2675	and	_	_	_	_
12-3	2676-2686	colleagues	person	giv	coref	15-8
12-4	2687-2698	demonstrate	_	_	_	_
12-5	2699-2711	associations	abstract[139]	giv[139]	_	_
12-6	2712-2719	between	abstract[139]	giv[139]	_	_
12-7	2720-2723	the	abstract[139]|abstract[141]	giv[139]|new[141]	_	_
12-8	2724-2733	metabolic	abstract[139]|person|abstract[141]	giv[139]|new|new[141]	_	_
12-9	2734-2742	syndrome	abstract[139]|abstract[141]	giv[139]|new[141]	_	_
12-10	2743-2746	and	abstract[139]	giv[139]	_	_
12-11	2747-2753	poorer	abstract[139]|abstract[143]	giv[139]|giv[143]	coref	16-33[183_143]
12-12	2754-2760	muscle	abstract[139]|object|abstract[143]	giv[139]|giv|giv[143]	coref	12-18
12-13	2761-2769	function	abstract[139]|abstract[143]	giv[139]|giv[143]	_	_
12-14	2770-2777	despite	_	_	_	_
12-15	2778-2781	the	abstract[145]	new[145]	_	_
12-16	2782-2791	generally	abstract[145]	new[145]	_	_
12-17	2792-2798	larger	abstract[145]	new[145]	_	_
12-18	2799-2805	muscle	object|abstract[145]	giv|new[145]	coref	12-31
12-19	2806-2810	size	abstract[145]	new[145]	_	_
12-20	2811-2813	in	abstract[145]	new[145]	_	_
12-21	2814-2824	overweight	abstract[145]|person[146]	new[145]|giv[146]	_	_
12-22	2825-2828	and	abstract[145]|person[146]	new[145]|giv[146]	_	_
12-23	2829-2834	obese	abstract[145]|person[146]	new[145]|giv[146]	_	_
12-24	2835-2840	older	abstract[145]|person[146]	new[145]|giv[146]	_	_
12-25	2841-2852	individuals	abstract[145]|person[146]	new[145]|giv[146]	_	_
12-26	2853-2854	,	_	_	_	_
12-27	2855-2865	indicating	_	_	_	_
12-28	2866-2877	accelerated	abstract[147]	new[147]	coref	17-7[186_147]
12-29	2878-2882	loss	abstract[147]	new[147]	_	_
12-30	2883-2885	of	abstract[147]	new[147]	_	_
12-31	2886-2892	muscle	abstract[147]|object|abstract[149]	new[147]|giv|giv[149]	coref|coref	17-31|17-31
12-32	2893-2900	quality	abstract[147]|abstract[149]	new[147]|giv[149]	_	_
12-33	2901-2903	is	_	_	_	_
12-34	2904-2910	common	_	_	_	_
12-35	2911-2913	in	_	_	_	_
12-36	2914-2918	this	person[150]	new[150]	_	_
12-37	2919-2929	population	person[150]	new[150]	_	_
12-38	2930-2931	.	_	_	_	_

#Text=Sarcopenia is generally considered a disease of ageing but there is no doubt that risk of developing sarcopenia is increased by numerous medical conditions .
13-1	2932-2942	Sarcopenia	abstract	giv	coref	13-18
13-2	2943-2945	is	_	_	_	_
13-3	2946-2955	generally	_	_	_	_
13-4	2956-2966	considered	_	_	_	_
13-5	2967-2968	a	abstract[152]	new[152]	_	_
13-6	2969-2976	disease	abstract[152]	new[152]	_	_
13-7	2977-2979	of	abstract[152]	new[152]	_	_
13-8	2980-2986	ageing	abstract[152]|abstract	new[152]|new	_	_
13-9	2987-2990	but	_	_	_	_
13-10	2991-2996	there	_	_	_	_
13-11	2997-2999	is	_	_	_	_
13-12	3000-3002	no	abstract[154]	new[154]	_	_
13-13	3003-3008	doubt	abstract[154]	new[154]	_	_
13-14	3009-3013	that	abstract[155]	giv[155]	_	_
13-15	3014-3018	risk	abstract[155]	giv[155]	_	_
13-16	3019-3021	of	_	_	_	_
13-17	3022-3032	developing	_	_	_	_
13-18	3033-3043	sarcopenia	abstract	giv	coref	14-6
13-19	3044-3046	is	_	_	_	_
13-20	3047-3056	increased	_	_	_	_
13-21	3057-3059	by	_	_	_	_
13-22	3060-3068	numerous	abstract[157]	new[157]	_	_
13-23	3069-3076	medical	abstract[157]	new[157]	_	_
13-24	3077-3087	conditions	abstract[157]	new[157]	_	_
13-25	3088-3089	.	_	_	_	_

#Text=Moreover , the presence of sarcopenia appears to consistently impact on prognosis of those with existing comorbidities .
14-1	3090-3098	Moreover	_	_	_	_
14-2	3099-3100	,	_	_	_	_
14-3	3101-3104	the	abstract[158]	new[158]	_	_
14-4	3105-3113	presence	abstract[158]	new[158]	_	_
14-5	3114-3116	of	abstract[158]	new[158]	_	_
14-6	3117-3127	sarcopenia	abstract[158]|abstract	new[158]|giv	coref	15-11
14-7	3128-3135	appears	_	_	_	_
14-8	3136-3138	to	_	_	_	_
14-9	3139-3151	consistently	_	_	_	_
14-10	3152-3158	impact	_	_	_	_
14-11	3159-3161	on	_	_	_	_
14-12	3162-3171	prognosis	abstract[160]	new[160]	_	_
14-13	3172-3174	of	abstract[160]	new[160]	_	_
14-14	3175-3180	those	abstract[160]	new[160]	_	_
14-15	3181-3185	with	abstract[160]	new[160]	_	_
14-16	3186-3194	existing	abstract[160]|abstract[161]	new[160]|new[161]	_	_
14-17	3195-3208	comorbidities	abstract[160]|abstract[161]	new[160]|new[161]	_	_
14-18	3209-3210	.	_	_	_	_

#Text=Indeed , the review by Han and colleagues demonstrates that sarcopenia is associated with increased progression of chronic disease , postoperative complications , length of hospital stay , all-cause mortality and cognitive impairment .
15-1	3211-3217	Indeed	_	_	_	_
15-2	3218-3219	,	_	_	_	_
15-3	3220-3223	the	abstract[162]	new[162]	_	_
15-4	3224-3230	review	abstract[162]	new[162]	_	_
15-5	3231-3233	by	abstract[162]	new[162]	_	_
15-6	3234-3237	Han	abstract[162]|person	new[162]|new	_	_
15-7	3238-3241	and	abstract[162]	new[162]	_	_
15-8	3242-3252	colleagues	abstract[162]|person	new[162]|giv	_	_
15-9	3253-3265	demonstrates	_	_	_	_
15-10	3266-3270	that	_	_	_	_
15-11	3271-3281	sarcopenia	abstract	giv	coref	16-4[175_0]
15-12	3282-3284	is	_	_	_	_
15-13	3285-3295	associated	_	_	_	_
15-14	3296-3300	with	_	_	_	_
15-15	3301-3310	increased	abstract[166]	new[166]	_	_
15-16	3311-3322	progression	abstract[166]	new[166]	_	_
15-17	3323-3325	of	abstract[166]	new[166]	_	_
15-18	3326-3333	chronic	abstract[166]|abstract[167]	new[166]|new[167]	coref	17-1[185_167]
15-19	3334-3341	disease	abstract[166]|abstract[167]	new[166]|new[167]	_	_
15-20	3342-3343	,	abstract[166]	new[166]	_	_
15-21	3344-3357	postoperative	abstract[166]|event[168]	new[166]|new[168]	_	_
15-22	3358-3371	complications	abstract[166]|event[168]	new[166]|new[168]	_	_
15-23	3372-3373	,	abstract[166]	new[166]	_	_
15-24	3374-3380	length	abstract[166]|time[169]	new[166]|new[169]	_	_
15-25	3381-3383	of	abstract[166]|time[169]	new[166]|new[169]	_	_
15-26	3384-3392	hospital	abstract[166]|time[169]|place|time[171]	new[166]|new[169]|new|new[171]	_	_
15-27	3393-3397	stay	abstract[166]|time[169]|time[171]	new[166]|new[169]|new[171]	_	_
15-28	3398-3399	,	abstract[166]	new[166]	_	_
15-29	3400-3409	all-cause	abstract[166]|abstract[172]	new[166]|new[172]	_	_
15-30	3410-3419	mortality	abstract[166]|abstract[172]	new[166]|new[172]	_	_
15-31	3420-3423	and	abstract[166]	new[166]	_	_
15-32	3424-3433	cognitive	abstract[166]|abstract[173]	new[166]|new[173]	coref	16-6[176_173]
15-33	3434-3444	impairment	abstract[166]|abstract[173]	new[166]|new[173]	_	_
15-34	3445-3446	.	_	_	_	_

#Text=The effects of sarcopenia on cognitive impairment are supported by an original study of community-dwelling older adults residing in rural areas of Korea which reported that physical frailty was significantly associated with poor cognitive function .
16-1	3447-3450	The	abstract[174]	new[174]	_	_
16-2	3451-3458	effects	abstract[174]	new[174]	_	_
16-3	3459-3461	of	abstract[174]	new[174]	_	_
16-4	3462-3472	sarcopenia	abstract[174]|abstract[175]	new[174]|giv[175]	coref	19-12[211_175]
16-5	3473-3475	on	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
16-6	3476-3485	cognitive	abstract[174]|abstract[175]|abstract[176]	new[174]|giv[175]|giv[176]	_	_
16-7	3486-3496	impairment	abstract[174]|abstract[175]|abstract[176]	new[174]|giv[175]|giv[176]	_	_
16-8	3497-3500	are	_	_	_	_
16-9	3501-3510	supported	_	_	_	_
16-10	3511-3513	by	_	_	_	_
16-11	3514-3516	an	abstract[177]	giv[177]	coref	17-14[188_177]
16-12	3517-3525	original	abstract[177]	giv[177]	_	_
16-13	3526-3531	study	abstract[177]	giv[177]	_	_
16-14	3532-3534	of	abstract[177]	giv[177]	_	_
16-15	3535-3553	community-dwelling	abstract[177]|place|person[179]	giv[177]|new|giv[179]	coref|coref	17-27[191_179]|17-27[191_179]
16-16	3554-3559	older	abstract[177]|person[179]	giv[177]|giv[179]	_	_
16-17	3560-3566	adults	abstract[177]|person[179]	giv[177]|giv[179]	_	_
16-18	3567-3575	residing	_	_	_	_
16-19	3576-3578	in	_	_	_	_
16-20	3579-3584	rural	place[180]	new[180]	_	_
16-21	3585-3590	areas	place[180]	new[180]	_	_
16-22	3591-3593	of	place[180]	new[180]	_	_
16-23	3594-3599	Korea	place[180]|place	new[180]|new	_	_
16-24	3600-3605	which	_	_	_	_
16-25	3606-3614	reported	_	_	_	_
16-26	3615-3619	that	_	_	_	_
16-27	3620-3628	physical	abstract[182]	new[182]	coref	17-10[187_182]
16-28	3629-3636	frailty	abstract[182]	new[182]	_	_
16-29	3637-3640	was	_	_	_	_
16-30	3641-3654	significantly	_	_	_	_
16-31	3655-3665	associated	_	_	_	_
16-32	3666-3670	with	_	_	_	_
16-33	3671-3675	poor	abstract[183]	giv[183]	_	_
16-34	3676-3685	cognitive	abstract[183]	giv[183]	_	_
16-35	3686-3694	function	abstract[183]	giv[183]	_	_
16-36	3695-3696	.	_	_	_	_

#Text=Liver disease is also associated with weight loss and physical frailty , and a population-based study reported that non-alcoholic fatty liver disease was more common in Korean adults with low muscle mass determined by CT , regardless of their obesity status .
17-1	3697-3702	Liver	object|abstract[185]	new|giv[185]	coref|coref|coref|coref	17-21|17-19[190_185]|17-21|17-19[190_185]
17-2	3703-3710	disease	abstract[185]	giv[185]	_	_
17-3	3711-3713	is	_	_	_	_
17-4	3714-3718	also	_	_	_	_
17-5	3719-3729	associated	_	_	_	_
17-6	3730-3734	with	_	_	_	_
17-7	3735-3741	weight	abstract[186]	giv[186]	_	_
17-8	3742-3746	loss	abstract[186]	giv[186]	_	_
17-9	3747-3750	and	_	_	_	_
17-10	3751-3759	physical	abstract[187]	giv[187]	_	_
17-11	3760-3767	frailty	abstract[187]	giv[187]	_	_
17-12	3768-3769	,	_	_	_	_
17-13	3770-3773	and	_	_	_	_
17-14	3774-3775	a	abstract[188]	giv[188]	_	_
17-15	3776-3792	population-based	abstract[188]	giv[188]	_	_
17-16	3793-3798	study	abstract[188]	giv[188]	_	_
17-17	3799-3807	reported	_	_	_	_
17-18	3808-3812	that	_	_	_	_
17-19	3813-3826	non-alcoholic	abstract[190]	giv[190]	coref	18-9[201_190]
17-20	3827-3832	fatty	abstract[190]	giv[190]	_	_
17-21	3833-3838	liver	object|abstract[190]	giv|giv[190]	coref	18-10
17-22	3839-3846	disease	abstract[190]	giv[190]	_	_
17-23	3847-3850	was	_	_	_	_
17-24	3851-3855	more	_	_	_	_
17-25	3856-3862	common	_	_	_	_
17-26	3863-3865	in	_	_	_	_
17-27	3866-3872	Korean	person[191]	giv[191]	ana	17-39[0_191]
17-28	3873-3879	adults	person[191]	giv[191]	_	_
17-29	3880-3884	with	person[191]	giv[191]	_	_
17-30	3885-3888	low	person[191]|quantity[193]	giv[191]|giv[193]	coref	18-17[204_193]
17-31	3889-3895	muscle	person[191]|object|quantity[193]	giv[191]|giv|giv[193]	coref	18-18
17-32	3896-3900	mass	person[191]|quantity[193]	giv[191]|giv[193]	_	_
17-33	3901-3911	determined	_	_	_	_
17-34	3912-3914	by	_	_	_	_
17-35	3915-3917	CT	object	giv	_	_
17-36	3918-3919	,	_	_	_	_
17-37	3920-3930	regardless	_	_	_	_
17-38	3931-3933	of	_	_	_	_
17-39	3934-3939	their	person|abstract[197]	giv|new[197]	_	_
17-40	3940-3947	obesity	abstract|abstract[197]	new|new[197]	_	_
17-41	3948-3954	status	abstract[197]	new[197]	_	_
17-42	3955-3956	.	_	_	_	_

#Text=Similarly , a study of Japanese patients with chronic liver disease reported that 50 % had low muscle mass , either alone or combined with low muscle strength .
18-1	3957-3966	Similarly	_	_	_	_
18-2	3967-3968	,	_	_	_	_
18-3	3969-3970	a	abstract[198]	new[198]	_	_
18-4	3971-3976	study	abstract[198]	new[198]	_	_
18-5	3977-3979	of	abstract[198]	new[198]	_	_
18-6	3980-3988	Japanese	abstract[198]|person[199]	new[198]|giv[199]	coref	19-14[212_199]
18-7	3989-3997	patients	abstract[198]|person[199]	new[198]|giv[199]	_	_
18-8	3998-4002	with	abstract[198]|person[199]	new[198]|giv[199]	_	_
18-9	4003-4010	chronic	abstract[198]|person[199]|abstract[201]	new[198]|giv[199]|giv[201]	coref	19-30[220_201]
18-10	4011-4016	liver	abstract[198]|person[199]|object|abstract[201]	new[198]|giv[199]|giv|giv[201]	coref	19-31
18-11	4017-4024	disease	abstract[198]|person[199]|abstract[201]	new[198]|giv[199]|giv[201]	_	_
18-12	4025-4033	reported	_	_	_	_
18-13	4034-4038	that	_	_	_	_
18-14	4039-4041	50	quantity[202]	new[202]	_	_
18-15	4042-4043	%	quantity[202]	new[202]	_	_
18-16	4044-4047	had	_	_	_	_
18-17	4048-4051	low	quantity[204]	giv[204]	_	_
18-18	4052-4058	muscle	object|quantity[204]	giv|giv[204]	coref	18-27
18-19	4059-4063	mass	quantity[204]	giv[204]	_	_
18-20	4064-4065	,	_	_	_	_
18-21	4066-4072	either	_	_	_	_
18-22	4073-4078	alone	_	_	_	_
18-23	4079-4081	or	_	_	_	_
18-24	4082-4090	combined	_	_	_	_
18-25	4091-4095	with	_	_	_	_
18-26	4096-4099	low	abstract[206]	new[206]	_	_
18-27	4100-4106	muscle	object|abstract[206]	giv|new[206]	coref	19-27
18-28	4107-4115	strength	abstract[206]	new[206]	_	_
18-29	4116-4117	.	_	_	_	_

#Text=Interestingly , low serum zinc concentration was an independent predictor of sarcopenia in these patients suggesting zinc supplementation warrants further investigation as a strategy to prevent muscle declines in chronic liver disease .
19-1	4118-4131	Interestingly	_	_	_	_
19-2	4132-4133	,	_	_	_	_
19-3	4134-4137	low	abstract[209]	new[209]	coref	19-8[210_209]
19-4	4138-4143	serum	abstract|abstract[209]	new|new[209]	_	_
19-5	4144-4148	zinc	substance|abstract[209]	new|new[209]	coref	19-17
19-6	4149-4162	concentration	abstract[209]	new[209]	_	_
19-7	4163-4166	was	_	_	_	_
19-8	4167-4169	an	abstract[210]	giv[210]	_	_
19-9	4170-4181	independent	abstract[210]	giv[210]	_	_
19-10	4182-4191	predictor	abstract[210]	giv[210]	_	_
19-11	4192-4194	of	abstract[210]	giv[210]	_	_
19-12	4195-4205	sarcopenia	abstract[210]|abstract[211]	giv[210]|giv[211]	_	_
19-13	4206-4208	in	abstract[210]|abstract[211]	giv[210]|giv[211]	_	_
19-14	4209-4214	these	abstract[210]|abstract[211]|person[212]	giv[210]|giv[211]|giv[212]	_	_
19-15	4215-4223	patients	abstract[210]|abstract[211]|person[212]	giv[210]|giv[211]|giv[212]	_	_
19-16	4224-4234	suggesting	_	_	_	_
19-17	4235-4239	zinc	substance|person[215]	giv|new[215]	_	_
19-18	4240-4255	supplementation	abstract|person[215]	new|new[215]	_	_
19-19	4256-4264	warrants	person[215]	new[215]	_	_
19-20	4265-4272	further	abstract[216]	new[216]	_	_
19-21	4273-4286	investigation	abstract[216]	new[216]	_	_
19-22	4287-4289	as	abstract[216]	new[216]	_	_
19-23	4290-4291	a	abstract[216]	new[216]	_	_
19-24	4292-4300	strategy	abstract[216]	new[216]	_	_
19-25	4301-4303	to	_	_	_	_
19-26	4304-4311	prevent	_	_	_	_
19-27	4312-4318	muscle	object|abstract[218]	giv|new[218]	_	_
19-28	4319-4327	declines	abstract[218]	new[218]	_	_
19-29	4328-4330	in	abstract[218]	new[218]	_	_
19-30	4331-4338	chronic	abstract[218]|abstract[220]	new[218]|giv[220]	_	_
19-31	4339-4344	liver	abstract[218]|object|abstract[220]	new[218]|giv|giv[220]	_	_
19-32	4345-4352	disease	abstract[218]|abstract[220]	new[218]|giv[220]	_	_
19-33	4353-4354	.	_	_	_	_
